- Home
- BYRN vs XOMA Comparison
BYRN vs XOMA Comparison
Compare BYRN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- XOMA
- Stock Information
- Founded
- BYRN 2005
- XOMA 1981
- Country
- BYRN United States
- XOMA United States
- Employees
- BYRN N/A
- XOMA N/A
- Industry
- BYRN Industrial Machinery/Components
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- BYRN Miscellaneous
- XOMA Health Care
- Exchange
- BYRN Nasdaq
- XOMA Nasdaq
- Market Cap
- BYRN 326.8M
- XOMA 355.6M
- IPO Year
- BYRN N/A
- XOMA N/A
- Fundamental
- Price
- BYRN $21.31
- XOMA $30.20
- Analyst Decision
- BYRN Strong Buy
- XOMA Strong Buy
- Analyst Count
- BYRN 3
- XOMA 2
- Target Price
- BYRN $17.75
- XOMA $78.50
- AVG Volume (30 Days)
- BYRN 503.9K
- XOMA 32.1K
- Earning Date
- BYRN 10-09-2024
- XOMA 11-07-2024
- Dividend Yield
- BYRN N/A
- XOMA N/A
- EPS Growth
- BYRN N/A
- XOMA N/A
- EPS
- BYRN 0.10
- XOMA N/A
- Revenue
- BYRN $73,417,000.00
- XOMA $21,606,000.00
- Revenue This Year
- BYRN $98.26
- XOMA $488.61
- Revenue Next Year
- BYRN $28.91
- XOMA $27.42
- P/E Ratio
- BYRN $208.17
- XOMA N/A
- Revenue Growth
- BYRN 70.65
- XOMA 389.82
- 52 Week Low
- BYRN $5.11
- XOMA $14.33
- 52 Week High
- BYRN $21.83
- XOMA $33.78
- Technical
- Relative Strength Index (RSI)
- BYRN 66.84
- XOMA 52.12
- Support Level
- BYRN $17.83
- XOMA $29.20
- Resistance Level
- BYRN $21.62
- XOMA $31.24
- Average True Range (ATR)
- BYRN 1.50
- XOMA 1.40
- MACD
- BYRN 0.38
- XOMA -0.17
- Stochastic Oscillator
- BYRN 93.30
- XOMA 23.67
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia and Canada.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.